September 30, 2024

Anito-Cel Yields 100% Response Rate in R/R Myeloma – OncLive

September 29, 2024

IMS 2024 Myeloma Oral Sessions Day 4

The final day of presentations at the International Myeloma Society (IMS) meeting in Brazil provided updates on the use of various treatments for patients with relapsed and refractory multiple myeloma. Let us break down the key findings for you… Antibody Drug Conjugate Therapy Blenrep (belanatamab mafodotin) Results of a large trial of Blenrep (belanatamab mafodotin), […]

September 28, 2024

IMS 2024 Myeloma Oral Sessions Day 3

The third day of presentations at the International Myeloma Society (IMS) meeting in Brazil offered a glimpse into the potential of new treatment strategies for patients with relapsed/refractory multiple myeloma (RRMM) and provided additional updates on quadruplet regiments for newly diagnosed multiple myeloma (NDMM). Talvey-Based Combinations for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Talvey (talquetamab), […]

September 27, 2024

Cilta-cel: Key Therapy for Unmet Needs in Myeloma Treatment? – Targeted Oncology

September 27, 2024

IMS 2024 Myeloma Oral Sessions Day 2

Welcome to the second day of our recap of the latest findings on myeloma treatments reported at the International Myeloma Society (IMS) meeting in Rio De Janeiro, Brazil. Today gave us important updates on new treatment combinations for newly diagnosed multiple myeloma (NDMM), particularly patients ages 65 years and older, as well as a new […]